Anthony Hughes 报道：Bambusa Therapeutics Inc. 提交首次公开募股（IPO）申请，以帮助资助其治疗湿疹和其他炎症疾病药物的试验。
Therapeutics Inc. filed for a initial public offering to help fund trials of its drugs to treat eczema and other inflammation disorders.
据周五向美国证券交易委员会提交的文件显示，这家总部位于波士顿的公司正在研发长效双特异性抗体，以满足每年超过 1500 亿美元的全球免疫学和炎症市场中未被满足的需求，该市场涵盖皮肤、呼吸、胃肠道和自身免疫性疾病。
The Boston-based company is working on long-acting bispecific antibodies to treat unmet needs in the more than $150 billion-a-year global immunology and inflammation market, encompassing skin, respiratory, gastroenterology and autoimmune diseases, according to a filing Friday with the US Securities and Exchange Commission.
Bambusa 成立于 2024 年，通过早前收购 BioNTech SE 旗下一个部门的资产获得了其首批候选药物，第一款用于治疗特应性皮炎（俗称湿疹），第二款用于治疗包括呼吸系统和过敏性疾病在内的其他炎症性疾病。
Started in 2024, Bambusa secured its lead drug candidates through its earlier acquisition of assets from a unit of BioNTech SE, the first to treat atopic dermatitis, commonly known as eczema, and the second to treat other inflammatory disorders including respiratory and allergic diseases.
该公司的主要投资者包括 Salvia Investment、RA Capital Management、德国亿万富翁 Thomas Strüngmann 关联的实体、总部位于旧金山的医疗健康投资机构 BVF Partners、KKR & Co. 控制的 Dawn Biopharma 以及总部位于香港的 INCE Capital。
The company’s biggest investors include Salvia Investment, RA Capital Management, entities affiliated with German billionaire Thomas Strüngmann, San Francisco-based healthcare investor BVF Partners, KKR & Co.-controlled Dawn Biopharma and Hong Kong-based INCE Capital.
文件显示，联合创始人、前 BioNTech 高管徐珊珊（Shanshan Xu）实益持有 Bambusa 21.5% 的股份。
Co-founder Shanshan Xu, a former BioNTech executive, beneficially owns 21.5% of Bambusa, the filing shows.
据当时的声明称，Bambusa 于 11 月完成了一轮融资，现有投资者 RA Capital、Janus Henderson Investors 和 Dawn Biopharma 参与了投资。
Bambusa completed a funding round in November with participation from existing investors including RA Capital, Janus Henderson Investors and Dawn Biopharma, according to a statement at the time.
文件显示，该轮融资筹集了 3310 万美元，估值较该年度早些时候的 8900 万美元融资轮大幅提升。
The financing raised $33.1 million at a substantial valuation step-up from an $89 million round earlier that year, the filing shows.
截至 6 月底，Bambusa 拥有 7150 万美元的现金及等价物。
At the end of June, Bambusa had $71.5 million of cash and equivalents.
文件显示，截至 2026 年 6 月 30 日的六个月内，公司在无收入的情况下净亏损 2240 万美元，而去年同期净亏损 1300 万美元，同样无收入。
The company had a net loss of $22.4 million on no revenue for the six months ended June 30, 2026, versus a net loss of $13.0 million on no revenue for the corresponding period a year earlier, the filing shows.
该 IPO 由美国银行、Evercore Inc.、瑞银集团和 Cantor Fitzgerald 领衔承销。
The IPO is being led by Bank of America Corp., Evercore Inc., UBS Group AG and Cantor Fitzgerald.
Bambusa 预计其股票将在纳斯达克全球精选市场上市交易，代码为 BBTX。
Bambusa expects its shares to trade on the Nasdaq Global Select Market under the symbol BBTX.